Official ESCRS | European Society of Cataract & Refractive Surgeons

Enhancement of pseudophakic refractive errors with sulcus-fixated supplementary IOLs after 5 years.

Session Details

Session Title: Cataract 2
Session Date/Time: Saturday 21/02/2015 | 08:30-11:00
Paper Time: 10:36
Venue: Hall 1
First Author: : G.Kahraman AUSTRIA
Co Author(s): :    M. Amon   F. Prager           

Abstract Details


To present clinical results of a recently introduced, hydrophilic acrylic, foldable, single piece, sulcus-fixated supplementary posterior chamber intraocular lens (Sulcoflex®, Rayner ltd. East Sussex, UK) after 5 years of follow-up


Academic Teaching Hospital of St. John, Vienna, Austria Department of Ophthalmology


This prospective, non-randomised, study included 47 eyes that received a secondary intraocular lens (Sulcoflex 653L®) to correct residual refractive error post cataract surgery. Clinical and refractive outcomes were evaluated. All IOLs were implanted with an injector through a 2.75 mm clear cornea incision in the ciliary sulcus. Postoperative examinations were performed after 1, 6 months and after 3 and 5 years. The study protocol included the assessment of visual acuity (UCVA, BCVA), specular microscopy and scheimpflug photography.


Surgeries were performed without any complication in all cases; Mean Follow up was 29 months (range 12 to 84 months). No intra- or postoperative complications were detected. The postoperative refraction remained stabile at all visits. The refraction of 45 eyes (96.6 % ) were within ±0.50 Diopters. IOP was within the normal range at all visits. No iris chafing was documented, and in all cases, a good distance was observed between the iris and the Sulcoflex Pseudophakic Supplementary IOL. A good distance was also observed between the supplementary IOL and the primary implant. No additive IOL exchange was necessary.


The Sulcoflex IOL was well tolerated in all study eyes. Secondary implantation of the Sulcoflex IOL in the ciliary sulcus was a safe and predictable option for patients with pseudophakic refractive errors.

Financial Disclosure:

One or more of the authors gains financially from product or procedure presented, One or more of the authors travel has been funded, fully or partially, by a competing company

Back to previous